Eli Lilly and Company (LLY) – Competition to Novo Nordisk

Eli Lilly and Company (LLY)(Q2FY23)

Stock Performance – Eli Lilly’s stock price showed an upward trend in past 3-months. It gave 18.41% returns during the period. The stock price increased by 76.8% in past 1-year. The stock has a 52- week high of $601.84 and its 52-week low is $309.20.

In the past 3 years, the stock has given returns of 266.04%. LLY has a 50-day moving Avg. and 200-day moving Avg. of $526.51 and $417.83, respectively.

Quater Performance: LLY revenue increased 28% in Q2FY23, as a result of volume-driven growth from Mounjaro, Verzenio, Jardiance and Taltz, as well as $579mn from the sale of rights for Baqsimi. Excluding revenue from Baqsimi, and COVID-19 antibodies in 2022, revenue in Q2 2023 increased 22%. The revenue increased by 7% to $15.27bn in 1HFY23 as compared to $14.29bn in 1HFY22

Company Guidance for FY23 – Revenue guidance increased by $2.2bn to the range of $33.4 to $33.9bn. Approximately $1.5bn of this increase is driven by business development activity, including the sales of rights for the olanzapine portfolio, which closed in July 2023, and Baqsimi, with the remainder reflecting strong underlying business performance

Highlights

In late August, Eli Lilly announced promising results for its drug, Retevmo, in the treatment of a specific type of thyroid cancer. This development marks a significant advancement in the field of thyroid cancer treatment and underscores the potential efficacy of Retevmo as a therapeutic option for this condition.

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Drug Sales (Actual)
– Drug Sales (Forecast)
– Economic Value Added Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages: 35

To download the previous quarter’s equity/report CLICK HERE

To Download other equity/reports CLICK HERE

Follow our LinkedIn page for more updates.